Free Trial

Xeris Biopharma (XERS) Competitors

Xeris Biopharma logo
$4.76 +0.03 (+0.53%)
Closing price 07/3/2025 02:59 PM Eastern
Extended Trading
$4.76 0.00 (0.00%)
As of 07/3/2025 04:50 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

XERS vs. KYMR, MOR, CRNX, ALVO, IMVT, CPRX, HCM, OGN, AMRX, and MIRM

Should you be buying Xeris Biopharma stock or one of its competitors? The main competitors of Xeris Biopharma include Kymera Therapeutics (KYMR), MorphoSys (MOR), Crinetics Pharmaceuticals (CRNX), Alvotech (ALVO), Immunovant (IMVT), Catalyst Pharmaceuticals (CPRX), HUTCHMED (HCM), Organon & Co. (OGN), AMNEAL PHARMACEUTICALS (AMRX), and Mirum Pharmaceuticals (MIRM). These companies are all part of the "pharmaceutical products" industry.

Xeris Biopharma vs. Its Competitors

Xeris Biopharma (NASDAQ:XERS) and Kymera Therapeutics (NASDAQ:KYMR) are both medical companies, but which is the superior stock? We will compare the two companies based on the strength of their earnings, institutional ownership, media sentiment, risk, valuation, dividends, profitability and analyst recommendations.

Xeris Biopharma has a beta of 0.66, meaning that its stock price is 34% less volatile than the S&P 500. Comparatively, Kymera Therapeutics has a beta of 2.18, meaning that its stock price is 118% more volatile than the S&P 500.

Xeris Biopharma has higher revenue and earnings than Kymera Therapeutics. Xeris Biopharma is trading at a lower price-to-earnings ratio than Kymera Therapeutics, indicating that it is currently the more affordable of the two stocks.

CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings Ratio
Xeris Biopharma$222.55M3.34-$54.84M-$0.30-15.85
Kymera Therapeutics$47.07M61.99-$223.86M-$3.10-14.45

In the previous week, Kymera Therapeutics had 20 more articles in the media than Xeris Biopharma. MarketBeat recorded 21 mentions for Kymera Therapeutics and 1 mentions for Xeris Biopharma. Xeris Biopharma's average media sentiment score of 0.67 beat Kymera Therapeutics' score of 0.56 indicating that Xeris Biopharma is being referred to more favorably in the media.

Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment
Xeris Biopharma
0 Very Positive mention(s)
0 Positive mention(s)
1 Neutral mention(s)
0 Negative mention(s)
0 Very Negative mention(s)
Positive
Kymera Therapeutics
6 Very Positive mention(s)
0 Positive mention(s)
5 Neutral mention(s)
1 Negative mention(s)
0 Very Negative mention(s)
Positive

Xeris Biopharma presently has a consensus price target of $6.25, indicating a potential upside of 31.44%. Kymera Therapeutics has a consensus price target of $59.11, indicating a potential upside of 31.91%. Given Kymera Therapeutics' stronger consensus rating and higher probable upside, analysts plainly believe Kymera Therapeutics is more favorable than Xeris Biopharma.

Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score
Xeris Biopharma
0 Sell rating(s)
1 Hold rating(s)
5 Buy rating(s)
0 Strong Buy rating(s)
2.83
Kymera Therapeutics
0 Sell rating(s)
1 Hold rating(s)
17 Buy rating(s)
1 Strong Buy rating(s)
3.00

Xeris Biopharma has a net margin of -20.25% compared to Kymera Therapeutics' net margin of -409.07%. Xeris Biopharma's return on equity of 0.00% beat Kymera Therapeutics' return on equity.

Company Net Margins Return on Equity Return on Assets
Xeris Biopharma-20.25% N/A -12.07%
Kymera Therapeutics -409.07%-30.11%-25.65%

42.8% of Xeris Biopharma shares are owned by institutional investors. 6.5% of Xeris Biopharma shares are owned by insiders. Comparatively, 16.0% of Kymera Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth.

Summary

Kymera Therapeutics beats Xeris Biopharma on 9 of the 17 factors compared between the two stocks.

Get Xeris Biopharma News Delivered to You Automatically

Sign up to receive the latest news and ratings for XERS and its competitors with MarketBeat's FREE daily newsletter.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding XERS and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
Skip Chart

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Skip Chart

XERS vs. The Competition

MetricXeris BiopharmaMED IndustryMedical SectorNASDAQ Exchange
Market Cap$742.83M$2.43B$5.56B$9.04B
Dividend YieldN/A1.67%5.22%3.99%
P/E Ratio-15.859.3527.6620.25
Price / Sales3.34687.53423.00177.43
Price / CashN/A158.5936.8958.10
Price / Book-23.784.588.035.67
Net Income-$54.84M$31.34M$3.18B$249.21M
7 Day Performance1.17%3.25%2.93%3.28%
1 Month Performance3.82%3.46%1.72%3.95%
1 Year Performance125.36%0.77%34.39%20.98%

Xeris Biopharma Competitors List

CompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)
XERS
Xeris Biopharma
3.9133 of 5 stars
$4.76
+0.5%
$6.25
+31.4%
+125.4%$742.83M$222.55M-15.85290Positive News
KYMR
Kymera Therapeutics
3.1608 of 5 stars
$43.64
-1.1%
$59.61
+36.6%
+48.1%$2.87B$47.07M-14.08170Analyst Forecast
Insider Trade
MOR
MorphoSys
N/A$18.96
flat
N/AN/A$2.86B$238.28M-5.45730News Coverage
CRNX
Crinetics Pharmaceuticals
3.306 of 5 stars
$28.76
-4.0%
$74.56
+159.2%
-31.8%$2.81B$1.04M-7.53210
ALVO
Alvotech
3.5251 of 5 stars
$9.12
-0.2%
$18.00
+97.4%
-24.2%$2.76B$491.98M24.651,032
IMVT
Immunovant
1.4074 of 5 stars
$16.00
-0.6%
$38.33
+139.6%
-37.5%$2.75BN/A-5.84120
CPRX
Catalyst Pharmaceuticals
4.9217 of 5 stars
$21.70
-0.4%
$32.83
+51.3%
+42.5%$2.66B$491.73M13.8280
HCM
HUTCHMED
1.346 of 5 stars
$15.05
-0.3%
$19.00
+26.2%
-13.9%$2.63B$630.20M0.001,811
OGN
Organon & Co.
4.8971 of 5 stars
$9.68
-1.8%
$18.00
+86.0%
-49.9%$2.56B$6.40B3.364,000Trending News
AMRX
AMNEAL PHARMACEUTICALS
3.1972 of 5 stars
$8.09
-0.5%
$11.60
+43.4%
+28.3%$2.55B$2.79B-202.208,100High Trading Volume
MIRM
Mirum Pharmaceuticals
3.7347 of 5 stars
$50.89
-0.4%
$65.50
+28.7%
+45.0%$2.53B$336.89M-31.61140News Coverage
Analyst Downgrade

Related Companies and Tools


This page (NASDAQ:XERS) was last updated on 7/6/2025 by MarketBeat.com Staff
From Our Partners